Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy

BJU International

Volumn 101, Issue 2, 2008, Pages 232-237

  Shariat, Shahrokh F ^a,c   Svatek, Robert S ^a   Kabbani, Wareef ^a   Walz, Jochen ^b   Lotan, Yair ^a   Karakiewicz, Pierre I ^b   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Progression; Prostatic neoplasms; Radical prostatectomy; Stage; Syndecan 1

Indexed keywords

SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE COURSE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SURGICAL TECHNIQUE; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 37349122445     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07181.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 : 106 30
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002 167 : 528 34
3. Shariat SF, Khoddami SM, Saboorian H et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004 171 : 1122 7
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy [see comments]. JAMA 1999 281 : 1591 7
5. Bernfield M, Gotte M, Park PW et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999 68 : 729 77
6. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004 2 : 3
7. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996 28 : 63 7
8. Chen D, Adenekan B, Chen L et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004 63 : 402 7
9. Kiviniemi J, Kallajoki M, Kujala I et al. Altered expression of syndecan-1 in prostate cancer. APMIS 2004 112 : 89 97
10. Zellweger T, Ninck C, Mirlacher M et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003 55 : 20 9
11. Henson DE, Hutter RV, Farrow G. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of american pathologists. Task Force Examination Specimens Removed from Patients with Prostate Cancer. Arch Pathol Lab Med 1994 118 : 779 83
12. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006 106 : 1047 53
13. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993 71 : 2031 40
14. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001 19 : 1030 9
15. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 291 : 1325 32
16. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005 23 : 8192 7
17. Bernfield M, Kokenyesi R, Kato M et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992 8 : 365 93
18. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997 327 : 1 16
19. Sanderson RD, Hinkes MT, Bernfield M. Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratify. J Invest Dermatol 1992 99 : 390 6
20. Vainio S, Jalkanen M, Bernfield M, Saxen L. Transient expression of syndecan in mesenchymal cell aggregates of the embryonic kidney. Dev Biol 1992 152 : 221 32
21. Elenius K, Salmivirta M, Inki P, Mali M, Jalkanen M. Binding of human syndecan to extracellular matrix proteins. J Biol Chem 1990 265 : 17837 43
22. Koda JE, Rapraeger A, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. Cell surface proteoglycan as a receptor for interstitial collagens. J Biol Chem 1985 260 : 8157 62
23. Maeda T, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006 25 : 1408 12
24. Mathe M, Suba Z, Nemeth Z et al. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 2006 42 : 493 500
25. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005 68 : 97 106
26. Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999 112 : 377 83
27. Kambham N, Kong C, Longacre TA, Natkunam Y. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005 13 : 304 10
28. Divi RL, Dragan YP, Pitot HC, Poirier MC. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 2001 22 : 1693 9
29. Bauer KD, de la Torre-Bueno J, Diel IJ et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000 6 : 3552 9
30. Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002 20 : 3165 75
31. Braunschweig T, Chung JY, Hewitt SM. Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics 2005 2 : 325 36